This study describes a novel approach for CRC therapy in which NR4A1 antagonists not only inhibit pro-oncogenic NR4A1-regulated genes/pathways but also enhance immune surveillance by targeting PD-L1 and reversing T-cell exhaustion in tumors and in spleen. This evidence concerns the gene CD274 and colorectal carcinoma.